Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Improving survival outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL) remains a clinical challenge. Relapsed disease has a poor prognosis despite the use of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome positive (Ph(+) ALL) cases and immunotherapeutic approaches, including...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Moujalled, Donia M., Hanna, Diane T., Hediyeh-zadeh, Soroor, Pomilio, Giovanna, Brown, Lauren, Litalien, Veronique, Bartolo, Ray, Fleming, Shaun, Chanrion, Maïa, Banquet, Sébastien, Maragno, Ana-Leticia, Kraus-Berthier, Laurence, Schoumacher, Marie, Mullighan, Charles G., Georgiou, Angela, White, Christine A., Lessene, Guillaume, Huang, David C. S., Roberts, Andrew W., Geneste, Olivier, Rasmussen, Lorna, Davis, Melissa J., Ekert, Paul G., Wei, Andrew, Ng, Ashley P., Khaw, Seong L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Lymphoid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322969/
https://ncbi.nlm.nih.gov/pubmed/32569380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001416
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi